Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080472 | 0.90 | TRPV1 (0.32) | TRPV1EIF4A3PIM1CSNK2A2CSNK2B | |
| SCHEMBL18080470 | 0.88 | TRPV1 (0.32) | TRPV1EIF4A3PIM1CSNK2A2CSNK2B | |
| SCHEMBL18080460 | 0.88 | TRPV1 (0.32) | TRPV1EIF4A3PIM1CSNK2A2CSNK2B | |
| SCHEMBL18080468 | 0.86 | PIM1 (0.34) | TRPV1PIM1CSNK2A2CSNK2BPIM3 | |
| SCHEMBL18080477 | 0.83 | PDE3B (0.32) | — | |
| SCHEMBL18080462 | 0.82 | TRPV1 (0.32) | TRPV1EIF4A3PIM1CSNK2A2CSNK2B | |
| SCHEMBL18080505 | 0.82 | L3MBTL1 (0.30) | — | |
| SCHEMBL18080463 | 0.82 | EIF4A3 (0.33) | TRPV1EIF4A3PIM1CSNK2A2CSNK2B | |
| SCHEMBL18081800 | 0.81 | SLC9A1 (0.30) | — | |
| SCHEMBL18080458 | 0.81 | PIM1 (0.33) | TRPV1EIF4A3PIM1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | TRPV1 3709/4885EIF4A3 1031/4885PIM1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.